Phase I Pharmacokinetic Study of Novel HIV-1 Capsid Inhibitor Lenacapavir Supports Potential for Every-6-Month SC Dosing

July 6-10, 2020; Virtual
Results demonstrate that this novel investigational first-in-class HIV-1 capsid inhibitor was generally well tolerated after single-dose administration in healthy volunteers, with PK supportive of a 6-month dosing interval.
Format: Microsoft PowerPoint (.ppt)
File Size: 228 KB
Released: July 10, 2020


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Drs. Jean Rene Anderson and William Short speak to the balancing act when considering HIV treatments during pregnancy, from Clinical Care Options (CCO)

Jean Rene Anderson, MD William R. Short, MD, MPH, AAHIVS Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: August 12, 2022 Expired: August 11, 2023

ANDES: Wk 48 safety and efficacy of generic darunavir/ritonavir + lamivudine for initial HIV treatment, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Expert summaries of ART treatment initiation in treatment-naive PWH, including rapid and same-day ART starts, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS
Program Director
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Released: August 4, 2022

Week 48 results from ALLIANCE study of BIC/FTC/TAF vs DTG plus FTC/TDF for HIV/HBV coinfection, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings